About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Viewpoint - Shares of pharmaceutical giant Moderna (MRNA) experienced a significant decline after the company revised its 2025 revenue forecast downward by $1 billion [1][4]. Revenue Forecast - Moderna now projects its revenue for the current year to be between $1.5 billion and $2.5 billion, a decrease from the previous estimate of $2.5 billion to $3.5 billion made in September [2]. - The company anticipates that most of this revenue will be generated in the second half of the year, primarily from sales of its Covid-19 and respiratory syncytial virus (RSV) vaccines [2][4]. Expense Management - Moderna plans to implement a $1 billion reduction in expenses for the current year, with an additional $500 million cut expected in 2026 [2]. Stock Performance - The stock price of Moderna fell over 20% intraday to $33.44, effectively negating gains made the previous week following the first reported bird-flu death in the U.S. [3]. - Over the past year, Moderna's stock has lost approximately two-thirds of its value and is significantly below its all-time high of nearly $490 reached in August 2021 during the COVID-19 pandemic [3][4].

Moderna's (MRNA -20.84%) sales are slowing down, and Moderna stock is going down -- a lot.The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated investors on its 2024 performance and released new guidance for 2025. Moderna in 2024...and 2025Moderna estimates it ended 2024 with somewhere between $3 billion and $3.1 billion in product sales as it shifted its business toward treating COVID-19 as an "endemic" illness rather than a novel and spreading pandemic. CEO Sté ...

Summary of Key Points Core Viewpoint - Moderna Inc has lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, reflecting a $1 billion reduction from previous estimates due to weaker demand for its Covid-19 and RSV vaccines [1] Group 1: Financial Performance - The adjustment in revenue forecast indicates that most of the revenue is expected to materialize in the second half of 2025 [1] - The stock price of Moderna has dropped 24% to $32.11, marking its lowest level since April 2020 and indicating a significant decline in market confidence [2] - Moderna is facing its third consecutive annual loss and has already decreased more than 22% in the first two weeks of January 2025 [2] Group 2: Market Sentiment and Trading Activity - Options traders are actively speculating, with 40,000 puts and 77,000 calls exchanged, which is four times the average intraday volume [3] - The most popular options are the January 2025 38 call and the 34.50 call, with new positions being opened in both [3] - The sentiment shift is reflected in Moderna's Schaeffer's put/call open interest ratio (SOIR) of 52%, which is in the low 1st percentile of annual readings, indicating a more call-biased stance among short-term options traders [4]

Summary of Key Points Core Viewpoint - Moderna Inc has lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, reflecting a $1 billion reduction from previous estimates due to weaker demand for its Covid-19 and RSV vaccines [1] Company Performance - The stock price of Moderna Inc dropped 24% to $32.11, marking its lowest level since April 2020 and indicating a significant decline in market confidence [2] - The company is facing its third consecutive annual loss and has already decreased more than 22% in the first two weeks of January, highlighting a steep recovery challenge for 2025 [2] Market Activity - Options trading activity has surged, with 40,000 puts and 77,000 calls exchanged, which is four times the average intraday volume, indicating heightened speculation among traders [3] - The most popular options are the January 2025 38 call and the 34.50 call, with new positions being opened in both [3] Sentiment Shift - There is a notable shift in sentiment as indicated by Moderna's Schaeffer's put/call open interest ratio (SOIR) of 52%, which is in the low 1st percentile of annual readings, suggesting that short-term options traders are currently more call-biased [4]

Moderna Inc. MRNA stock plunged on Monday after the company announced business updates and progress across its pipeline. Moderna says it enters 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses.The company will present at the 43rd Annual J.P. Morgan Healthcare Conference.In September, Moderna unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, enabling a focus on ten prioritized p ...

Moderna on Monday lowered its 2025 sales guidance by roughly $1 billion due to a few potential headwinds later this year, as the biotech company continues to cut costs and expand its portfolio.Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year. The majority of those sales will come from Moderna's Covid shot and newly launched vaccine for respiratory syncytial virus, according to a release.The guidance is down from a prior ...

mRNA Cancer Vaccines Market Overview - The mRNA cancer vaccine market is poised for significant transformation with over 60 candidates currently in clinical trials [2] - No mRNA cancer vaccines have received regulatory approval yet, but the pipeline is growing with innovative therapies [2] - The market is driven by advancements in technology and a deeper understanding of tumor immunology [5] - Industry analysts project significant market expansion as more candidates progress through clinical trials and demonstrate efficacy [5] Key Developments in Clinical Trials - BioNTech's BNT111, an mRNA cancer vaccine targeting melanoma, showed positive topline data in a Phase 2 clinical trial in July 2024 [2] - BNT111 is designed to encode four melanoma-associated antigens and is being tested in combination with the anti-PD-1 antibody cemiplimab [2] - The combination of BNT111 and cemiplimab aims to enhance the efficacy of existing immunotherapies through synergistic immune system activation [3] - Over 60 mRNA cancer vaccines are in clinical trials, with 2 vaccines in Phase III [7] Technological Advantages of mRNA Vaccines - mRNA cancer vaccines can be rapidly designed and manufactured, offering a flexible platform for targeting various cancer types [4] - Unlike traditional vaccines, mRNA vaccines instruct cells to produce specific antigens, prompting a direct immune response against cancer cells [4] - The success of mRNA technology in COVID-19 vaccines has accelerated investment and research in oncology applications [4] Market Expansion and Future Outlook - The mRNA cancer vaccine market is expected to expand significantly, with applications beyond melanoma, including breast, prostate, and colorectal cancers [5] - The first commercial mRNA cancer vaccine approval is expected by 2029 [7] - The US and China dominate mRNA cancer vaccine clinical trials, with over 45 vaccines being tested in these regions [7] - Skin cancer is the most targeted indication in mRNA vaccine trials, with over 10 vaccines in development [7] Conclusion - The mRNA cancer vaccine landscape is rapidly evolving, with promising data emerging from clinical trials [6] - Personalized mRNA therapies offer a new frontier in cancer treatment, potentially improving outcomes in oncology [6] - The growth of this market signifies a transformative shift in cancer immunotherapy, offering hope for more effective and tailored treatment options [6]

Stock Performance and Market Reaction - Shares of Moderna surged over 12% following news of the first confirmed death from H5N1 bird flu in the US, reaching a peak of 14% before retreating to $47 53 after hours [1] - The stock has since declined further, trading at $44 56, down 6 25% from its previous close [2] - Despite the recent surge, the stock has dropped over 60% in 2024, making it one of the worst-performing stocks across all sectors [10] Pipeline and Future Prospects - Moderna is forecasting approvals for 10 new vaccines in the next three years, including three candidates planned for launch in 2025 [3] - The company is collaborating with Merck & Co to develop personalized cancer vaccines, with its most advanced candidate, V940-Keytruda, entering Phase III trials in 2024 [5] - Moderna received a $250 million upfront payment from Merck under the partnership, with both companies sharing development costs and potential profits equally [7] Financials and Revenue Streams - Moderna generates approximately $3 billion in annual revenue, with a significant portion coming in the third and fourth quarters due to flu season [8] - The company reported $1 9 billion in revenue in its November earnings report, bringing the total for the first three quarters of 2024 to $2 2 billion [9] - Moderna has a $9 billion cash balance, which is substantial compared to some biotech companies with products already on the market [8] R&D and Profitability Concerns - Moderna's R&D spending is projected to be around $4 7 billion annually, revised downward but still significant [10] - The company is currently not profitable, as the funds from its COVID-19 vaccine profits have dried up, contributing to the stock's poor performance [10] Analyst Sentiment and Price Targets - Analysts have a consensus Hold rating on Moderna, with a 12-month price target of $78 83, representing a 76 92% upside from the current price [4] - The stock has a high forecast of $179 00 and a low forecast of $40 00, indicating mixed sentiment among analysts [4] - Despite being on Barron's list of stocks to watch in 2025, Moderna was not included in MarketBeat's list of top five stocks recommended by analysts [13]

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi ... [+] Images/GHI/UCG/Universal Images Group via Getty Images)UCG/Universal Images Group via Getty ImagesThe stock price of Moderna saw a 12% jump on Tuesday, January 7, amid rising cases of Covid-19 and flu in the U.S. Along with Moderna, stocks of other vaccine makers also saw an uptick. Novavax was up 11%, while BioNTech ADR was up 5%. According to the CDC, influenza’s test positivity rate increased from 13.6% for the w ...